Regeneration of pancreatic beta-cell mass for the treatment of diabetes

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Introduction: The study of the endocrine compartment of the pancreas (the islets of Langerhans) is of great translational interest, as strategies aimed at restoring its mass could become therapies for glycemic dysregulation in type 1 and 2 diabetes mellitus, drug-related diabetes following diabetogenic therapies or hyperglycemic disturbances following the treatment of cancer and nesidioblastosis. Such strategies generally fall under one of the 'three Rs,' namely, replacement (islet transplantation and stem cell differentiation), reprogramming (chiefly from the exocrine compartment of the pancreas) and regeneration (replication and induction of endogenous stem cells). Areas covered: This expert opinion focuses on the latter, as islets are known to regenerate under specific circumstances of physiological (e.g., pregnancy), pathological (e.g., obesity, hyperglycemia, mutations in the glucose-sensing pathway) or experimental (e.g., partial pancreatectomy, cellophane wrapping, partial duct ligation) nature. This review presents the different models of pancreatic regeneration, which encompass the replication of existing beta-cells, reversible epithelial-to-mesenchymal transition and the reactivation of resident stem cells. Expert opinion: Rather than a set mechanism, the pancreas appears to possess a wide range of facultative regeneration pathways. These are discussed in the context of the development of potential strategies aimed at restoring beta-cell function in insulin-dependent diabetes.

Original languageEnglish
Pages (from-to)731-741
Number of pages11
JournalExpert Opinion on Biological Therapy
Volume12
Issue number6
DOIs
StatePublished - Jun 1 2012

Fingerprint

Insulin-Secreting Cells
Medical problems
Stem cells
Islets of Langerhans
Regeneration
Stem Cells
Expert Testimony
Nesidioblastosis
Cellophane
Exocrine Pancreas
Islets of Langerhans Transplantation
Pancreatectomy
Epithelial-Mesenchymal Transition
Type 1 Diabetes Mellitus
Hyperglycemia
Ducts
Type 2 Diabetes Mellitus
Ligation
Cell Differentiation
Pancreas

Keywords

  • Beta-cell replication
  • Glucokinase-activating mutations
  • Islet regeneration
  • Pregnancy

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Regeneration of pancreatic beta-cell mass for the treatment of diabetes. / Dominguez-Bendala, Juan; Inverardi, Luca A; Ricordi, Camillo.

In: Expert Opinion on Biological Therapy, Vol. 12, No. 6, 01.06.2012, p. 731-741.

Research output: Contribution to journalArticle

@article{255622682afd4ebe8a9fdd66eb9b64d2,
title = "Regeneration of pancreatic beta-cell mass for the treatment of diabetes",
abstract = "Introduction: The study of the endocrine compartment of the pancreas (the islets of Langerhans) is of great translational interest, as strategies aimed at restoring its mass could become therapies for glycemic dysregulation in type 1 and 2 diabetes mellitus, drug-related diabetes following diabetogenic therapies or hyperglycemic disturbances following the treatment of cancer and nesidioblastosis. Such strategies generally fall under one of the 'three Rs,' namely, replacement (islet transplantation and stem cell differentiation), reprogramming (chiefly from the exocrine compartment of the pancreas) and regeneration (replication and induction of endogenous stem cells). Areas covered: This expert opinion focuses on the latter, as islets are known to regenerate under specific circumstances of physiological (e.g., pregnancy), pathological (e.g., obesity, hyperglycemia, mutations in the glucose-sensing pathway) or experimental (e.g., partial pancreatectomy, cellophane wrapping, partial duct ligation) nature. This review presents the different models of pancreatic regeneration, which encompass the replication of existing beta-cells, reversible epithelial-to-mesenchymal transition and the reactivation of resident stem cells. Expert opinion: Rather than a set mechanism, the pancreas appears to possess a wide range of facultative regeneration pathways. These are discussed in the context of the development of potential strategies aimed at restoring beta-cell function in insulin-dependent diabetes.",
keywords = "Beta-cell replication, Glucokinase-activating mutations, Islet regeneration, Pregnancy",
author = "Juan Dominguez-Bendala and Inverardi, {Luca A} and Camillo Ricordi",
year = "2012",
month = "6",
day = "1",
doi = "10.1517/14712598.2012.679654",
language = "English",
volume = "12",
pages = "731--741",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Regeneration of pancreatic beta-cell mass for the treatment of diabetes

AU - Dominguez-Bendala, Juan

AU - Inverardi, Luca A

AU - Ricordi, Camillo

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Introduction: The study of the endocrine compartment of the pancreas (the islets of Langerhans) is of great translational interest, as strategies aimed at restoring its mass could become therapies for glycemic dysregulation in type 1 and 2 diabetes mellitus, drug-related diabetes following diabetogenic therapies or hyperglycemic disturbances following the treatment of cancer and nesidioblastosis. Such strategies generally fall under one of the 'three Rs,' namely, replacement (islet transplantation and stem cell differentiation), reprogramming (chiefly from the exocrine compartment of the pancreas) and regeneration (replication and induction of endogenous stem cells). Areas covered: This expert opinion focuses on the latter, as islets are known to regenerate under specific circumstances of physiological (e.g., pregnancy), pathological (e.g., obesity, hyperglycemia, mutations in the glucose-sensing pathway) or experimental (e.g., partial pancreatectomy, cellophane wrapping, partial duct ligation) nature. This review presents the different models of pancreatic regeneration, which encompass the replication of existing beta-cells, reversible epithelial-to-mesenchymal transition and the reactivation of resident stem cells. Expert opinion: Rather than a set mechanism, the pancreas appears to possess a wide range of facultative regeneration pathways. These are discussed in the context of the development of potential strategies aimed at restoring beta-cell function in insulin-dependent diabetes.

AB - Introduction: The study of the endocrine compartment of the pancreas (the islets of Langerhans) is of great translational interest, as strategies aimed at restoring its mass could become therapies for glycemic dysregulation in type 1 and 2 diabetes mellitus, drug-related diabetes following diabetogenic therapies or hyperglycemic disturbances following the treatment of cancer and nesidioblastosis. Such strategies generally fall under one of the 'three Rs,' namely, replacement (islet transplantation and stem cell differentiation), reprogramming (chiefly from the exocrine compartment of the pancreas) and regeneration (replication and induction of endogenous stem cells). Areas covered: This expert opinion focuses on the latter, as islets are known to regenerate under specific circumstances of physiological (e.g., pregnancy), pathological (e.g., obesity, hyperglycemia, mutations in the glucose-sensing pathway) or experimental (e.g., partial pancreatectomy, cellophane wrapping, partial duct ligation) nature. This review presents the different models of pancreatic regeneration, which encompass the replication of existing beta-cells, reversible epithelial-to-mesenchymal transition and the reactivation of resident stem cells. Expert opinion: Rather than a set mechanism, the pancreas appears to possess a wide range of facultative regeneration pathways. These are discussed in the context of the development of potential strategies aimed at restoring beta-cell function in insulin-dependent diabetes.

KW - Beta-cell replication

KW - Glucokinase-activating mutations

KW - Islet regeneration

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=84861308520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861308520&partnerID=8YFLogxK

U2 - 10.1517/14712598.2012.679654

DO - 10.1517/14712598.2012.679654

M3 - Article

VL - 12

SP - 731

EP - 741

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 6

ER -